Nanobiotix ADRs Jump Over 50% After Agreement With J & J ' s Janssen Pharmaceutical

American depositary receipts of Nanobiotix (NBTX) jumped over 50% in early trading on Monday after it entered into an agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceutical to co-develop a drug to treat cancer. Nanobiotix said it will co-develop and commercialize the NBTXR3 drug, designed…#nanobiotix #johnsonjohnson #nbtxr3 #linabio #abiomed #medtech #newjersey
Source: Reuters: Health - Category: Consumer Health News Source Type: news